Unresectable hepatocellular carcinoma: Transarterial chemoembolization combined with lenvatinib in combination with programmed death-1 inhibition is a possible approach

doi:10.4251/wjgo.v16.i10.4042

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (287)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

243

Sum=255

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=21

Oct 15, 2024 (publication date) through Oct 19, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastrointest Oncol. Oct 15, 2024; 16(10): 4042-4044
Published online Oct 15, 2024. doi: 10.4251/wjgo.v16.i10.4042

Unresectable hepatocellular carcinoma: Transarterial chemoembolization combined with lenvatinib in combination with programmed death-1 inhibition is a possible approach

Fei-Yu Zhao, Dong-Yu Wang, Nian-Song Qian

Fei-Yu Zhao, Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People’s Liberation Army General Hospital, Beijing 100853, China

Dong-Yu Wang, Department of Nephrology, General Hospital of the People’s Liberation Army, Beijing 100853, China

Nian-Song Qian, Senior Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People’s Liberation Army General Hospital, Beijing 100091, China

Author contributions: Qian NS came up with the idea for the article; Zhao FY carried out the writing of the article; and Wang DY was responsible for revising the article.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4. 0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Nian-Song Qian, MD, Chief Physician, Senior Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People’s Liberation Army General Hospital, No. 28 Fuxing Road, Beijing 100091, China. qianniansong1@163. com

Received: February 28, 2024
Revised: May 11, 2024
Accepted: June 11, 2024
Published online: October 15, 2024
Processing time: 211 Days and 8.4 Hours

Core Tip

Core Tip: This article focuses on the efficacy of transarterial chemoembolization combined with lenvatinib in combination with programmed death 1 inhibitors in patients with advanced hepatocellular carcinoma. Although transarterial chemoembolization as well as lenvatinib in combination with programmed death 1 have both achieved some efficacy in advanced hepatocellular carcinoma, more clinical evidence is needed on the efficacy of all three combinations.